Chris Leamon, CSO at Fusion Therapeutics - Acquisition of Endocyte, Career reflections and more

Chris Leamon, CSO at Fusion Therapeutics - Acquisition of Endocyte, Career reflections and more

In this episode, I talked with Dr. Chris Leamon, Chief Scientific Officer at Fusion Pharmaceuticals, where he shares his journey in the biotech industry, discussing his early influences, the founding of Endocyte, and . He also discusses the challenges faced in drug development, the importance of leadership during workforce reductions, and the lessons learned from trial failures. Chris emphasizes the significance of execution, continuous learning, and building a strong team in the biotech field.

Here's what you're in:

  • What made Chris pursue a career in oncology?
  • Why did Chris join Fusion Pharmaceuticals?
  • What are big mistakes companies are still making today?


Timestamps:

02:41 Early Influences and Career Beginnings

06:43 Transitioning into Radiotherapeutics Field

13:36 The Process of Pivoting Trials

16:50 Dealing with Workforce Reduction

20:53 Joining Fusion Pharmaceuticals and Future Aspirations

24:36 Insights on Trial Failures and Learning Experiences

29:17 Hiring Practices and Building a Strong Team

34:11 Advice for Aspiring Biotech Professionals


About Chris

Dr. Chris Leamon is the Chief Scientific Officer at Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company that specializes in developing targeted alpha therapeutics for the treatment of cancer. He is also a scientific co-founder of Endocyte, the company that developed Pluvicto, and he has been an executive associated with two biotech acquisitions over the past six years: Endocyte (purchased by Novartis in Dec. 2018) and Fusion Pharmaceuticals (purchased by Astra Zeneca in June, 2024). Dr. Leamon earned his PhD in Biochemistry at Purdue University.


Connect with Chris

LinkedIn: https://www.linkedin.com/in/chris-leamon-393639b/

Company Website: https://fusionpharma.com/


About me

My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate.

In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.


Connect with me:

LinkedIn:https://www.linkedin.com/in/charles-spence-clinical/

Website: https://www.discera-search.com/



Opinions and comments expressed by the guest do not represent the company and are fully their own.



Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(74)

Eliot Forster, CEO at Levicept on 30 Years in Pharma, Running a Six-Person Biotech, and the Future of European Drug Development

Eliot Forster, CEO at Levicept on 30 Years in Pharma, Running a Six-Person Biotech, and the Future of European Drug Development

In this episode, I talked with Eliot Forster, CEO of Levicept, a neurophysiologist-turned biotech veteran with 30+ years of experience across Big Pharma and a series of CEO roles. We get into clinical...

7 Sep 45min

Michael Zaiac, Medical Affairs Lead for Oncology at Daiichi Sankyo on 30 Years of Hiring Lessons, The ADC Wave, and Building Teams in a Fast-Moving Pipeline

Michael Zaiac, Medical Affairs Lead for Oncology at Daiichi Sankyo on 30 Years of Hiring Lessons, The ADC Wave, and Building Teams in a Fast-Moving Pipeline

In this episode, I talked with Michael Zaiac, Medical Affairs Lead for Oncology across Europe and Canada at Daiichi Sankyo — a trained surgical oncologist who walked away from the operating table, mov...

24 Aug 39min

Juho Jalkanen, CEO at Faron Pharmaceuticals on From Surgeon to CEO, Rethinking Boards, and Fighting for the Right Science

Juho Jalkanen, CEO at Faron Pharmaceuticals on From Surgeon to CEO, Rethinking Boards, and Fighting for the Right Science

In this episode, I talked with Dr. Juho Jalkanen, CEO of Faron Pharmaceuticals — a publicly listed Finnish biotech building novel immunotherapies for blood cancers. Juho's path is unlike most you'll h...

10 Aug 37min

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

In this episode, I talked with Dr. Tobias Kampfenkel, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine. Tobias spent nearly a decade at Janssen building ...

15 Juni 39min

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

In this episode, I talked with Sofia Heigis, Chief Executive Officer of OncoPeptides, about a career path that did not start where she expected. Sofia originally wanted to move into clinical operation...

31 Maj 38min

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

In this episode, I talked with Jens Lindberg, CEO of Medivir AB, a Swedish biotech developing innovative therapies in liver cancer and rare disease. Jens brings over 30 years of late-stage development...

18 Maj 33min

Hubert Truebel,  Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

Hubert Truebel, Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

In this episode, I talked with Hubert Truebel, Managing Director at DEBRA Research, to discover a career that wasn’t built traditionally—but through creating opportunities where none formally existed....

4 Maj 28min

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

In this episode, I talked with Sampreet Ramachandra, Head of the Hematology Business Unit at Novartis Germany, about what it really takes to lead high-stakes launches — and what leadership looks like ...

30 Mars 42min

Populärt inom Business & ekonomi

framgangspodden
varvet
rss-jossan-nina
rss-borsens-finest
svd-tech-brief
24fragor
avanzapodden
badfluence
uppgang-och-fall
rss-inga-dumma-fragor-om-pengar
lastbilspodden
fill-or-kill
rss-dagen-med-di
rss-kort-lang-analyspodden-fran-di
rikatillsammans-om-privatekonomi-rikedom-i-livet
tabberaset
bathina-en-podcast
kapitalet-en-podd-om-ekonomi
borsmorgon
affarsvarlden